SCHEMBL23958823

SCHEMBL23958823

CC(C)(O)c1cc(C(=O)CN(Cc2ccccc2)Cc2ccccc2)nc(-c2ccc(F)cc2)c1F

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 3/20 0.42
MMP1 P03956 2/20 0.42
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
THRB P10828 1/20 0.39
MEP1B Q16820 1/20 0.37
MAPT P10636 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
CNR1 P21554 1/20 0.36
KMT2A Q03164 2/20 0.36
PTGDR2 Q9Y5Y4 4/20 0.36
DHODH Q02127 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 1/20 0.36
MAPK1 P28482 1/20 0.36
CFTR P13569 1/20 0.36
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23958718 0.93 CNR1 (0.44) MMP13MMP1MEP1BCNR1KMT2A
SCHEMBL23958724 0.92 CNR1 (0.35) MMP13MMP1MMP2MMP9THRB
SCHEMBL23958619 0.81 CFTR (0.41) MAPTCNR1PTGDR2DHODHL3MBTL1
SCHEMBL30007475 0.81 CFTR (0.41) MAPTCNR1PTGDR2DHODHL3MBTL1
SCHEMBL28909146 0.79 MAPT (0.40) MMP13MMP1MMP2MMP9THRB
SCHEMBL30211226 0.76 MAPT (0.37) MMP13MMP1MMP2MMP9THRB
SCHEMBL23958824 0.76 MAPT (0.37) MMP13MMP1MMP2MMP9THRB
SCHEMBL25686954 0.75 MAPT (0.36) MMP13MMP1MMP2MMP9THRB
SCHEMBL23958842 0.74 MAPT (0.38) MMP13MMP1MMP2MMP9THRB
SCHEMBL25689048 0.71 CFTR (0.37) MAPTCNR1L3MBTL1MAPK1CFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
WO-2021214136-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES ACE2, SIRT7, ACE MMP13 2935/4885MMP1 3417/4885MMP2 2628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.